All In Biotech

Drug Trial Radar · NCT00360555

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America

Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,584 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,584

Actual

Start

Jul 2006

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Aug 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • flibanserinDrug

    flibanserin 25 mg b.i.d

  • flibanserin 50mgDrug

    flibanserin 50mg qhs/b.i.d.

  • flibanserin 100mgDrug

    flibanserin 50 mg b.i.d/100mg qhs

  • placeboDrug

    placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.Time frame: baseline to 28 weeks
  2. Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.Time frame: baseline to 24 weeks

Locations

77 sites in 2 countries. Site status is shown where the registry gives one.

  • 511.75.01015 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 511.75.01028 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.75.01051 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 511.75.01063 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 511.75.01017 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 511.75.01014 Boehringer Ingelheim Investigational Site

    Encinitas, California

  • 511.75.01042 Boehringer Ingelheim Investigational Site

    Fair Oaks, California

  • 511.75.01022 Boehringer Ingelheim Investigational Site

    Irvine, California

  • 511.75.01005 Boehringer Ingelheim Investigational Site

    La Jolla, California

  • 511.75.01053 Boehringer Ingelheim Investigational Site

    Sacremento, California

  • 511.75.01045 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.75.01065 Boehringer Ingelheim Investigational Site

    Aurora, Colorado

  • 511.75.01003 Boehringer Ingelheim Investigational Site

    Englewood, Colorado

  • 511.75.01030 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 511.75.01066 Boehringer Ingelheim Investigational Site

    Coral Gables, Florida

  • 511.75.01040 Boehringer Ingelheim Investigational Site

    Fort Meyers, Florida

  • 511.75.01001 Boehringer Ingelheim Investigational Site

    Gainesville, Florida

  • 511.75.01062 Boehringer Ingelheim Investigational Site

    Hollywood, Florida

  • 511.75.01032 Boehringer Ingelheim Investigational Site

    Ocala, Florida

  • 511.75.01047 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 511.75.01073 Boehringer Ingelheim Investigational Site

    Palm Bay, Florida

  • 511.75.01035 Boehringer Ingelheim Investigational Site

    Sarasota, Florida

  • 511.75.01010 Boehringer Ingelheim Investigational Site

    South Miami, Florida

  • 511.75.01041 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 511.75.01033 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 511.75.01002 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 511.75.01006 Boehringer Ingelheim Investigational Site

    Sandy Springs, Georgia

  • 511.75.01023 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 511.75.01031 Boehringer Ingelheim Investigational Site

    Fort Wayne, Indiana

  • 511.75.01050 Boehringer Ingelheim Investigational Site

    Lafayette, Louisiana

  • 511.75.01043 Boehringer Ingelheim Investigational Site

    Bingham Farms, Michigan

  • 511.75.01025 Boehringer Ingelheim Investigational Site

    Chaska, Minnesota

  • 511.75.01024 Boehringer Ingelheim Investigational Site

    Chesterfield, Missouri

  • 511.75.01009 Boehringer Ingelheim Investigational Site

    Kansas City, Missouri

  • 511.75.01060 Boehringer Ingelheim Investigational Site

    Las Vegas, Nevada

  • 511.75.01004 Boehringer Ingelheim Investigational Site

    New Brunswick, New Jersey

  • 511.75.01037 Boehringer Ingelheim Investigational Site

    Chapel Hill, North Carolina

  • 511.75.01054 Boehringer Ingelheim Investigational Site

    Winston-Salem, North Carolina

  • 511.75.01069 Boehringer Ingelheim Investigational Site

    Beachwood, Ohio

  • 511.75.01012 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.